Deciphex
Nominated Award: Best Application of AI in a Startup
Website of Company: https://www.deciphex.com/
The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload.
Digital Pathology, seen as a great potential for productivity enhancement, has not fully delivered on that promise. Some ROI studies have, at best, demonstrated marginally positive return on investment with others demonstrating negative impact on cost post implementation.
We believe that digital pathology combined with artificial intelligence will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.
Deciphex plan to be at the forefront of this revolution with cleverly positioned solutions, that deliver on the biggest problems facing pathology today.
Reason for Nomination:
Patholytix is the only digital pathology solution proven to enable GLP Peer Review of non-clinical (drug safety) studies. Through strong relationships with the leading CROs, we offer an alternative strategy for the secure onboarding and review of studies. Our superior ergonomics in study management and image review along with integrated AI, significantly improves the efficiency of our pathologist users.
Patholytix AI delivers state of the art tools to help Pathologists reach critical decisions more quickly, and with greater confidence.
Integrated AI Models utilizing optimized training & deployment strategies support deeper analysis of whole slide images, giving greater insights to the pathologist.
We work with pathologists to develop AI solutions tailored to every need. Our rapid, easy to use ant integrated annotation workflow, powerful model architectures, quantitative pathology solutions provides AI based insights at any step of clinical and non-clinical drug development workflow that requires rapid and accurate tissue analysis.
Additional Information:
Donal O’Shea is a Founder & Chief Executive Officer of Deciphex.
Donal is an experienced corporate officer in the technology and diagnostics sectors, having 20 years of business leadership experience from start-up through to large corporate enterprise. Donal has considerable M&A experience. He has founded three companies and has senior management experience in Slidepath, Genetix, Leica Microsystems and Leica Biosystems.